TCF3 may promote tumor-associated pathologic angiogenesis, reshape the oxygen-depleted immune-cold tumor microenvironment, and significantly predict poor prognosis and unfavorable responses to VEGF-TKI therapy in patients with cancer, notably in KIRC and UVM. Here, TCF3 is linked to cancer.